Tabituximab barzuxetan indium In-111

N/A

Report date: 2025/10/20 14:43:21

Base Information

Drug NameTabituximab barzuxetan indium In-111

Drug Alias NameIndium 111-radiolabelled OTSA 101 - OncoTherapy ScienceOTSA 101 DTPA-111In111IN-OTSA-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Indium > 111In +[4]

Mechanisms of ActionWnt signalling pathway inhibitorsAnti-FZD10

TargetsFrizzled-10

Therapy Area/IndicationsSarcoma, Synovial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesOncotherapy Science, Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesOncotherapy Science, Inc

Active IndicationsN/A

Inactive IndicationsSarcoma, Synovial

Other Information

ATC CodeN/A